Relapsed or refractory Hodgkin lymphoma - brentuximab vedotin - initial authority application form (PB205)

Use this form to apply for initial PBS-subsidised treatment with brentuximab vedotin for patients with relapsed or refractory Hodgkin lymphoma.

Page last updated: 1 June 2025.
QC 36591